MicroRNAs as ideal biomarkers for the diagnosis of lung cancer

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10395-10407

  Guo, Zhiqiang ^a   Zhao, Chuncheng ^a   Wang, Zheng ^a  

^a Shanghai Putuo District Central Hospital   (China)

Author keywords

Diagnostic value; Lung cancer; Meta analysis; MicroRNAs

Indexed keywords

MICRORNA; TUMOR MARKER;

AREA UNDER THE CURVE; DIAGNOSTIC USE; GENETICS; HUMAN; LUNG NEOPLASMS; META ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AREA UNDER CURVE; HUMANS; LUNG NEOPLASMS; MICRORNAS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84922393435     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2330-1     Document Type: Article

References (55)

1. Siegel R,Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29. doi:10.3322/caac.21208.
2. Akamatsu H, Mori K, Naito T, Imai H, Ono A, Shukuya T, et al. Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer. 2014;14:18. doi:10.1186/1471-2407-14-18.
3. YouldenDR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol. 2008; 3 : 819-31. doi : 1 0.1097/JTO. 0b013e31818020eb.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. doi:10.3322/CA. 2007.0010.
5. Crino L,WederW, vanMeerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v103-115. doi:10. 1093/annonc/mdq207.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30. doi:10.3322/caac.21166.
7. Mazzone P, Jain P, Arroliga AC, Matthay RA. Bronchoscopy and needle biopsy techniques for diagnosis and staging of lung cancer. Clin Chest Med. 2002;23:137-158, ix.
8. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positronemission tomography and computed tomography. N Engl J Med. 2003;348:2500-7. doi:10.1056/NEJMoa022136.
9. Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, Prorok PC, et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer. 2005;47:9-15. doi:10.1016/j. lungcan.2004.06.007.
10. Aberle DR, Adams AM, Berg CD, BlackWC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409. doi:10. 1056/NEJMoa1102873.
11. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2011;91:579-87. doi:10.1038/labinvest.2010.194.
12. Ardizzoni A, CafferataMA, TiseoM, Filiberti R,Marroni P, Grossi F, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer. 2006;107:2842-9. doi:10.1002/cncr.22330.
13. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem. 2002;48:1931-7.
14. Ando S, Suzuki M, Yamamoto N, Iida T, Kimura H. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res. 2004;24:1941-6.
15. Molina R, Auge JM, Escudero JM, Marrades R, Vinolas N, Carcereny E, et al. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol. 2008;29:371-80.
16. Wiemer EA. The role ofmicroRNAs in cancer: no small matter. Eur J Cancer. 2007;43:1529-44. doi:10.1016/j.ejca.2007.04.002.
17. Hwang HW,Mendell JT.MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94:776-80. doi:10.1038/sj.bjc. 6603023.
18. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522-31. doi:10. 1038/nrg1379.
19. Lu J, Getz G,Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-8. doi:10.1038/nature03702.
20. Schipper HM, Maes OC, Chertkow HM, Wang E. MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Bio. 2007;1:263-74.
21. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11:426-37. doi: 10.1038/nrc3066.
22. Mraz M, Malinova K, Mayer J, Pospisilova S. MicroRNA isolation and stability in stored RNA samples. Biochem Biophys Res Commun. 2009;390:1-4. doi:10.1016/j.bbrc.2009.09.061.
23. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889-97.
24. Whiting PF, Rutjes AW,WestwoodME,Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann InternMed. 2011;155:529-36. doi: 10.7326/0003-4819-155-8-201110180-00009.
25. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323: 157-62.
26. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129-35.
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. doi:10.1136/bmj. 327.7414.557.
28. Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird's methodology to perform multivariate random effects metaanalyses. Stat Med. 2010;29:1282-97. doi:10.1002/sim.3602.
29. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58: 882-93. doi:10.1016/j.jclinepi.2005.01.016.
30. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 2010;67:170-6. doi:10.1016/j. lungcan.2009.04.004.
31. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Early detection of lung adenocarcinoma in sputum by a panel ofmicroRNA markers. Int J Cancer. 2010;127:2870-8. doi:10.1002/ijc.25289.
32. Jeong HC, Kim EK, Lee JH, Lee JM, Yoo HN, Kim JK. Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients. Mol Med Rep. 2011;4:383-7. doi:10.3892/mmr. 2011.430.
33. Li Y, Li W, Ouyang Q, Hu S, Tang J. Detection of lung cancer with blood microRNA-21 expression levels in Chinese population. Oncol Lett. 2011;2:991-4. doi:10.3892/ol.2011.351.
34. Wei J, Liu LK, GaoW, Zhu CJ, Liu YQ, Cheng T, et al. Reduction of plasma microRNA-21 is associated with chemotherapeutic response in patients with non-small cell lung cancer. Chin J Cancer Res. 2011;23:123-8. doi:10.1007/s11670-011-0123-2.
35. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011;4:575-86.
36. Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG, et al. Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med Oncol. 2012;29:3190-7. doi:10.1007/s12032-012-0303-z.
37. Ma Y, Tian Z, ZhangW. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol. 2012;138:2045-50. doi:10.1007/s00432- 012-1285-0.
38. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138:1659-66. doi:10.1007/s00432-012-1244-9.
39. Abd-El-Fattah AA, Sadik NA, Shaker OG, Aboulftouh ML. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem Biophys. 2013;67:875-84. doi:10.1007/s12013-013-9575-y.
40. Ma J, Li N, Guarnera M, Jiang F. Quantification of plasma miRNAs by digital PCR for cancer diagnosis. Biomark Insights. 2013;8:127-36 doi:10.4137/bmi.s13154.
41. Mozzoni P, Banda I, Goldoni M, Corradi M, Tiseo M, Acampa O, et al. Plasma and EBC microRNAs as early biomarkers of non-smallcell lung cancer. Biomarkers. 2013;18:679-86. doi:10.3109/ 1354750x.2013.845610.
42. Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013;22:540-8. doi:10.1097/CEJ.0b013e32835f3be9.
43. Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D, et al. Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC. Int J Mol Sci. 2013;14:10332-42. doi:10.3390/ijms140510332.
44. Zeng XL, Zhang SY, Zheng JF, Yuan H, Wang Y. Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer. Chin Med J (Engl). 2013;126:4510-6.
45. Gao F, Chang J, Wang H, Zhang G. Potential diagnostic value of miR-155 in serum from lung adenocarcinoma patients. Oncol Rep. 2014;31:351-7. doi:10.3892/or.2013.2830.
46. Shen J, Liao J, Guarnera MA, Fang H, Cai L, Stass SA, et al. Analysis of microRNAs in sputumto improve computed tomography for lung cancer diagnosis. J Thorac Oncol. 2014;9:33-40. doi:10. 1097/jto.0000000000000025.
47. Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, SchefflerM.miRNAs in lung cancer-studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer. 2009;9:353. doi:10.1186/1471-2407-9-353.
48. Bianchi F, Nicassio F, Marzi M, Belloni E, Dall'olio V, Bernard L, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011;3:495-503. doi:10.1002/ emmm.201100154.
49. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011;108:3713-8. doi:10.1073/pnas.1100048108.
50. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR- 1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol. 2011;6: 482-8. doi:10.1097/JTO.0b013e318208c785.
51. Chen X, Hu Z,WangW, Ba Y,Ma L, Zhang C, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer. 2012;130:1620-8. doi:10.1002/ ijc.26177.
52. Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT, et al. Serum microRNA biomarkers for detection of nonsmall cell lung cancer. PLoS One. 2012;7:e32307. doi:10.1371/ journal.pone.0032307.
53. Roa WH, Kim JO, Razzak R, Du H, Guo L, Singh R, et al. Sputum microRNA profiling: a novel approach for the early detection of nonsmall cell lung cancer. Clin Invest Med. 2012;35:E271.
54. Sanfiorenzo C, Ilie MI, Belaid A, Barlesi F, Mouroux J, Marquette CH, et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One. 2013;8:e54596. doi:10.1371/journal.pone.0054596.
55. Shen Y, Wang T, Yang T, Hu Q, Wan C, Chen L, et al. Diagnostic value of circulating microRNAs for lung cancer: a meta-analysis. Genet Test Mol Biomarkers. 2013;17:359-66. doi:10.1089/gtmb. 2012.0370.